4DMedical Secures $650.50 CMS Payment Per CT:VQ™ Scan
4DMedical has won a crucial US Medicare reimbursement for its CT, VQ™ lung imaging software, paving the way for rapid adoption across American hospitals. This milestone follows FDA clearance and promises to transform lung diagnostics with safer, faster scans.
- CMS confirms $650.50 reimbursement per CT, VQ™ scan
- Reimbursement adds to standard chest CT payments, boosting provider revenue
- Technology offers non-radioactive, contrast-free lung function assessment
- Supports both outpatient and inpatient hospital payment systems
- 4DMedical ready to commercially launch CT, VQ™ across the US
A Landmark Reimbursement Decision
4DMedical Limited (ASX – 4DX) has achieved a significant regulatory and commercial milestone with the U.S. Centers for Medicare & Medicaid Services (CMS) confirming reimbursement for its innovative CT – VQ™ ventilation-perfusion lung imaging software. Effective immediately, CMS will pay healthcare providers US$650.50 per CT – VQ™ scan under the Hospital Outpatient Prospective Payment System (OPPS), in addition to the standard chest CT scan fee. This reimbursement is a critical enabler for widespread adoption of the technology across American hospitals and imaging centers.
Transforming Lung Imaging Economics and Access
The CT – VQ™ software transforms routine CT scans into detailed functional lung assessments without the need for radioactive tracers or contrast agents. This not only improves patient safety but also simplifies logistics by eliminating separate nuclear medicine appointments. For healthcare providers, the new reimbursement structure creates a predictable revenue stream and reduces costs, especially in inpatient settings covered by Diagnosis-Related Group (DRG) payments. Importantly, CT – VQ™ integrates seamlessly into existing workflows without requiring costly new infrastructure.
Strategic Positioning for Commercial Launch
Following its recent FDA 510(k) clearance, 4DMedical is now positioned to accelerate commercial rollout of CT – VQ™ across the United States. CEO Andreas Fouras highlighted that securing reimbursement removes one of the biggest barriers to adoption, enabling immediate integration into clinical practice. The company plans to engage leading hospital groups, imaging networks, and academic institutions to expand access to this advanced diagnostic tool, which promises to improve patient care by enabling earlier and more precise lung disease detection.
Broader Implications for Respiratory Care
CT – VQ™’s ability to deliver comprehensive ventilation and perfusion analysis from a standard CT scan could democratize access to advanced lung imaging, particularly in facilities lacking nuclear medicine departments. This has the potential to benefit a wide range of patients, including those undergoing surgical or interventional pulmonology procedures who require detailed lung function assessment prior to treatment. The technology’s SaaS delivery model further facilitates rapid adoption without disrupting existing hospital IT systems.
Looking Ahead
With regulatory and reimbursement hurdles cleared and a strong cash position, 4DMedical is well placed to redefine functional lung imaging at scale. The company’s expanding portfolio, enhanced by recent AI capabilities, signals a broader ambition to transform respiratory diagnostics worldwide.
Bottom Line?
4DMedical’s Medicare win sets the stage for a US lung imaging revolution, but market uptake will be the true test.
Questions in the middle?
- How quickly will major US hospital networks adopt CT, VQ™ following reimbursement?
- What volume of scans does 4DMedical project in the first 12 months post-launch?
- Could private insurers follow Medicare’s lead to expand reimbursement coverage?
